ClinPhone will be exhibiting its complete range of clinical trial technology services at the 18th Annual DIA Euro Meeting.
(February 24, 2005) ClinPhone, the global leader in clinical technology solutions, will be exhibiting its complete range of clinical trial technology services at the 18th DIA Annual Euro Meeting, March 6–8 2006, Les Palais des Congres, Paris. Technologies being showcased include ePRO (Electronic Patient Reported Outcomes), ClinPhone's integration suite for Electronic Data Capture Systems (EDC) and Clinical Trial Management Software (CTMS), Randomization and Medication Management solutions. ClinPhone will also be debuting its recently launched Web-based Clinical Trial Management System (CTMS) at booths #53, 54 and 63.
Showcasing at DIA Europe is ClinPhone's solution for real-time electronic patient reported outcomes data. The 21 CFR part 11 compliant technology addresses concerns over limitations on data quality and integrity of paper diaries and questionnaires, by utilizing Interactive Voice Response (IVR) systems. ClinPhone ePRO is simple and intuitive to use, offering unparalleled diary compliance, study site access to patient data and simultaneous application in an unlimited numbers of languages and countries. ClinPhone will be presenting on electronic Patient Reported Outcomes on Wednesday 8 March (Track 6, ePRO tools between clinical research needs, technical opportunities and patient needs). Bill Byrom, Product Strategy Director at ClinPhone will be conducting a further ePRO presentation "Innovative ePRO Applications and their Contributions to Clinical Trials" during the show.
Also being demonstrated at booths #53, 54 and 63 is ClinPhone integration technology for EDC and CTMS systems. This offers customers a flexible interface between ClinPhone's real-time trial management systems and their EDC and/or CTMS software. This application creates an environment where critical randomization and dispensing data are seamlessly shared between systems in real-time. Unlike other integration solutions, ClinPhone Connect enables data to originate in either system and also offers protocol-specific integration touch-points.
ClinPhone will also be introducing the recently-launched TrialWorks® Web 2005, its innovative, globally scalable web-based CTMS. This system will be deployed by pharmaceutical, biotech and CRO organizations for the day-to-day tracking and reporting of regulatory and clinical information. The new Web-based version will be offered alongside TrialWorks® by ClinPhone v4.5 and ClinPhone's TrialWorks e-Service, enabling ClinPhone to offer its customers the "total" clinical trial management solution.
Other clinical trial solutions being demonstrated at the show include Randomization and Medication Management services. ClinPhone provides automated logistics management and drug supply chain management for clinical trials. The supply processes are controlled by a central computer accessed via telephone (IVR) and web (IWR) interfaces. ClinPhone's sophisticated medication management algorithms are the subject of continued research and development to optimize medication supply chain processes and provide the greatest medication savings and the most robust inventory control.
Patrick Hughes, Strategic Business Development and Marketing Director at ClinPhone, comments: "We are excited to be demonstrating our full range of clinical trial technology solutions at DIA Europe. ClinPhone has an unrivalled track record of innovation in the field of clinical trial management and we welcome this opportunity to unveil our services which offer centralized trial support to the global biopharmaceutical industry."
For further information on ClinPhone's clinical trial management solutions, please visit ClinPhone at booths #53, 54 and 63, 18th DIA Annual Euro Meeting, March 6–8 2006, Le Palais des Congres, Paris, France, or alternatively visit www.clinphone.com or email info@clinphone.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.